These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The small-molecule IAP antagonist AT406 inhibits pancreatic cancer cells in vitro and in vivo. Jiang Y; Meng Q; Chen B; Shen H; Yan B; Sun B Biochem Biophys Res Commun; 2016 Sep; 478(1):293-299. PubMed ID: 27387230 [TBL] [Abstract][Full Text] [Related]
4. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219 [TBL] [Abstract][Full Text] [Related]
5. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225 [TBL] [Abstract][Full Text] [Related]
6. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415. Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631 [TBL] [Abstract][Full Text] [Related]
7. Imperatorin induces Mcl-1 degradation to cooperatively trigger Bax translocation and Bak activation to suppress drug-resistant human hepatoma. Li X; Zeng X; Sun J; Li H; Wu P; Fung KP; Liu F Cancer Lett; 2014 Jun; 348(1-2):146-55. PubMed ID: 24680709 [TBL] [Abstract][Full Text] [Related]
8. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice. Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751 [TBL] [Abstract][Full Text] [Related]
9. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling. Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498 [TBL] [Abstract][Full Text] [Related]
10. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740 [TBL] [Abstract][Full Text] [Related]
11. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227 [TBL] [Abstract][Full Text] [Related]
12. Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting survivin and XIAP. Fan L; Sun G; Ma T; Zhong F; Wei W J Pineal Res; 2013 Sep; 55(2):174-83. PubMed ID: 23679681 [TBL] [Abstract][Full Text] [Related]
13. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents. Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma. Liu Y; Sun L; Su X; Guo S Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474 [TBL] [Abstract][Full Text] [Related]
15. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma. Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051 [TBL] [Abstract][Full Text] [Related]
18. Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells. Liao YJ; Bai HY; Li ZH; Zou J; Chen JW; Zheng F; Zhang JX; Mai SJ; Zeng MS; Sun HD; Pu JX; Xie D Cell Death Dis; 2014 Mar; 5(3):e1137. PubMed ID: 24651440 [TBL] [Abstract][Full Text] [Related]
19. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262 [TBL] [Abstract][Full Text] [Related]
20. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]